RxDoctor Payments Data

Sharon Martin

Family Medicine · Orbisonia, PANPI 1891884375

Payments from drug & device makers

$4,092in general payments, 2019–2025

Across 263 payments — averaging $15.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • GSK$467
  • Lilly USA, LLC$439
  • Boehringer Ingelheim$336
  • AstraZeneca$309
  • AbbVie$231
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$4,092100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,092 in reported general payments places this provider in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin229$191,203
EliquisApixaban140$98,932
OzempicSemaglutide71$72,957
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$37,547
MounjaroTirzepatide31$35,176
TrulicityDulaglutide33$32,398
XareltoRivaroxaban24$20,750
MyrbetriqMirabegron32$17,051
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog27$15,244
TradjentaLinagliptin18$13,743
FarxigaDapagliflozin Propanediol16$9,882
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$8,431
Breo ElliptaFluticasone/Vilanterol16$7,134
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog22$7,062
BrilintaTicagrelor12$6,478

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat$336$210,459259 claims
PfizerEliquis$42$98,932140 claims
Novo NordiskOzempic$1,198$72,95771 claims
Lilly USA, LLCMounjaro, Trulicity$439$67,57464 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$467$53,11290 claims
Johnson & JohnsonXarelto$78$20,75024 claims
Astellas Pharma US IncMyrbetriq$78$17,05132 claims
AstraZenecaFarxiga, Brilinta$309$16,36028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Orbisonia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →